Senate Hearing Criticizes FDA's Rare Disease Drug Review Process on February 27, 2026 Biohaven troriluzole disease treatments Drug Approval Infrequent Rare Diseases regulatory reform Senate hearing United States Food and Drug Administration +
Merck KGaA springs back into M&A game with $3.9B buyout of Pfizer spinout SpringWorks on April 28, 2025 Aggressive disease treatments Fibromatosis Gomekli KGaA Merck KGaA Neurofibromatosis 1 Ogsiveo Pfizer pharmaceutical acquisition SpringWorks +